Israel Active

Another experiment conducted by astronauts on the Axiom One Rakia mission to the International Space Station was the helmet of Israel’s Brain.Space (see previously). Here is a detailed description of the experiment and the implications for future space travel.

Israel’s NeoTX (see previously) is now conducting a Phase 2 trial of its naptumomab estafenatox (NAP) bacteria-coated, immunotherapy cancer treatment on 30 patients in the US. It is also enhancing an AstraZeneca checkpoint inhibitor. NeoTX has 3 Nobel prizewinners in its team.

Israel’s Biomica (see previously) has given 12 cancer patients, who had poor responses to immunotherapy, pills containing bacteria missing from their gut microbiome. In 2020, doctors at Sheba hospital used fecal bacteria to shrink the tumors of three cancer patients.

Scientists at Israel’s Weizmann Institute have made a vital discovery in how Candida infections are countered in healthy humans. Until the immune system’s TH17 T-Cell lymphocytes turn up, rare lymphoid cells (Aire-ILC3s) spring into action to hold back the potentially dangerous fungal infection.

Dr. Elad Jacoby - Head of cell therapy, Pediatric Hematology and Oncology at Israel’s Sheba Medical Center talks at Talpiot xmed 2022 about how they re-educate T-cells in the immune system to destroy cancers that used to take the lives of young children.

Scientists at Israel’s Technion Institute have developed an ultra-thin silicon-based membrane that speeds up the repair of damaged nerves. The material is wrapped around the nerve while the wound is open. When the wound is closed, the material is stimulated using near-infrared light.

Scientists at Tel Aviv University and Israel’s Volcani Institute developed the kit that Israeli astronaut Eytan Stibbe tested on his mission on the International Space Station. It proved that even under zero gravity, diagnosis known as CRISPR-Cas can identify viruses and bacteria infecting crew members.

Suboptimal polypharmacy is when medication for two or more chromic conditions clash. Israel’s FeelBetter has been deployed by Israel’s Leumit Healthcare and preliminary results show it can identify 70% of elderly patients at risk of hospitalization in the next 3 to 9 months.

Israel's Maccabi Healthcare Services HMO and health organizations in the United Arab Emirates have signed several deals to promote joint medical research and tech innovation. They focus on advancing personalized medicine and includes building a genomic research registry for the UAE.

Hebrew University startup ViroBlock has reported preliminary success of its platform for rapidly generating anti-viral therapies. Its channel blockers inhibit proteins expressed by current and emerging viruses, including COVID-19 and variants, influenza, Zika, West Nile, Hepatitis B and more.